13D Filing: Versant Venture Capital IV, L.P. and Crispr Therapeutics AG (CRSP)

 

Item 5.   Interest in Securities of the Issuer

 

Solely on behalf of, and only to the extent that it relates to the Reporting Persons Item 5 of the Original Filing is hereby amended as follows:

 

The following information with respect to the Common Stock of the Issuer by the Reporting Persons filing this statement on Schedule 13D is provided as of the date of this filing:

 

Reporting Persons		Shares Held Directly		Sole Voting Power		Shared Voting Power		Sole Dispositive Power		Shared Dispositive Power		Beneficial Ownership		Percentage of Class (1)
VVC IV		2,736,032		2,736,032		0		2,736,032		0		2,736,032		6.74	%
VSF IV		16,224		16,224		0		16,224		0		16,224		0.04	%
VV IV		0		0		2,752,256		0		2,752,256		2,752,256		6.78	%
VVC V		1,629,204		1,629,204		0		1,629,204		0		1,629,204		4.01	%
VAF V		47,801		47,801		0		47,801		0		47,801		0.12	%
VOA		52,987		52,987		0		52,987		0		52,987		0.13	%
VV V		0		0		1,729,992		0		1,729,992		1,729,992		4.26	%
VVC CAN		123,994		123,994		0		123,994		0		123,994		0.31	%
VV V CAN GP		0		0		123,994		0		123,994		123,994		0.31	%
VV V CAN		0		0		123,994		0		123,994		123,994		0.31	%

 

(1) This calculation is based upon 40,591,669 Common Shares outstanding as of August 7, 2017, as reported in the Issuers 10-Q filed with the SEC  on August 10, 2017.

 

(a)    Except as set forth herein, none of the Reporting Persons has effected any transactions in shares of the Issuers Common Stock during the last 60 days.

(b)    No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the shares of Common Stock beneficially owned by any of the Reporting Persons.

(c)     Not applicable.

(d)  Not applicable.

(e)  Not applicable.

 

13